Patient Feedback — T2D on Reddit (2024–2025)
Reddit communities (r/diabetes, r/diabetes_t2, r/Mounjaro, r/Mounjaro_ForType2) contain hundreds of patient-reported experiences with Mounjaro (tirzepatide) for Type 2 diabetes. These are anecdotal and self-selected — not clinical data — but they illuminate real-world patient experience, particularly for populations not well-represented in SURPASS trials (e.g. patients with very high baseline HbA1c, patients on high-dose insulin, long-duration diabetics, patients in the NHS). Evidence strength is classified as alleged for this vault.
The dominant pattern across threads from 2024–2025 is dramatic HbA1c reduction over 3–12 months, often accompanied by weight loss and reduction or elimination of other diabetes medications. Reported HbA1c drops include: 13.4→5.8 (1 year), 10.9→5.4 (4 months), 8.1→5.0 (>1 year), 7.4→5.2 (7 months), 13.4 to 5.8 (6 months), 13→4.8 (1 year). These exceed typical SURPASS trial results, possibly because Reddit users with more severe baseline disease are more motivated to post, and because concurrent dietary change confounds the benefit attribution.
Insulin users: Several Reddit accounts describe striking insulin dose reductions. One user went from >100 units/day to 5–10 units of basal-only insulin (not needed daily), while also on Jardiance for heart failure. Another with cystic fibrosis-related diabetes went from 30U/day to approximately 3U/day on the lowest 2.5mg dose. These reports are consistent with SURPASS-6 (basal insulin patients reducing titrated dose by 75% with tirzepatide), but self-reported Reddit accounts lack clinical verification.
Long-duration diabetics: One r/Mounjaro_ForType2 thread focused on patients diabetic for 15+ years who had cycled through multiple GLP-1 agents, insulin, and oral medications. This group still showed benefit with Mounjaro, though some reported more modest absolute HbA1c drops than recently-diagnosed users — consistent with declining beta-cell reserve over time. The 50yo woman describing decades of prediabetes before T2D onset, reporting A1C from ~7 to low 5s on 15mg, illustrates a pattern of late-stage successful escalation.
Side effects in practice: Nausea is the most commonly reported adverse effect, particularly at dose escalation. Several users described strategies: taking the injection at night to sleep through nausea, starting low doses, staying at a well-tolerated dose rather than escalating. One user preferred to revert to Trulicity (dulaglutide) due to feeling “loopy” on Mounjaro. One user experienced emergency cholecystectomy after 5 months of Mounjaro, but attributed it to pre-existing biliary colic history — consistent with the elevated gallbladder disease risk documented in Gallbladder Disease.
Ontology Patient Feedback T2D Reddit [relates] Tirzepatide Patient Feedback T2D Reddit [relates] Patient Feedback T2D Drugs.com WebMD Patient Feedback T2D Reddit [relates] Insulin-Use Reduction Patient Feedback T2D Reddit [relates] Nausea and Vomiting Risk Patient Feedback T2D Reddit [relates] Gallbladder Disease
Key Themes Summary
| Theme | Predominant experience | Caveats |
|---|---|---|
| HbA1c reduction | Very large (often 3–8+ pp); exceeds SURPASS averages | Self-selected, dietary confounders |
| Insulin reduction | Dramatic (50–90%+ reduction in some accounts) | Unverified; concurrent dietary change |
| Weight loss | Substantial (25-70+ lbs typical in positive posts) | Confounded by diet |
| GI side effects | Common, especially dose escalation; manageable for most | Tolerable with titration strategies |
| Cost/access | Significant US barrier without insurance | UK users on NHS report free access |
| Long-duration T2D | Still responds; may need higher dose; more modest relative gains | Consistent with beta-cell reserve depletion |
Connections
- Tirzepatide — relates (anecdotal patient evidence)
- Patient Feedback T2D Drugs.com WebMD — relates (companion structured review data)
- Insulin-Use Reduction — relates (patient-reported insulin reductions)
- Nausea and Vomiting Risk — relates (most common side effect reported)
- Gallbladder Disease — relates (one user case)
- Stopping Effects and Treatment Dependence — relates (users fear stopping; supply shortage causes anxiety)